Sarcopenia Clinical Trial
Official title:
Impact of Neuromuscular Electrical Stimulation on Physical Function in Older Adults
The purpose of this placebo controlled clinical trial is to examine the effects of of
neuromuscular electrical stimulation (NMES) training on physical activity, muscle function,
self-efficacy, and blood markers [e.g., brain-derived neurotrophic factor (BDNF)] in older
adults.
It is hypothesized that 4-weeks of NMES will increase 1) physical activity, 2) muscle
function, 3) self-efficacy, and 4) BDNF in older adults.
Sarcopenia is a destructive progressive cycle of impaired physical function resulting in loss
of muscle mass, strength, and self-confidence in ability to perform physical activities,
compounded by difficulty walking and ultimately reduced physical activity levels for many
older adults. Neuromuscular electrical stimulation (NMES) is a common therapeutic modality
used to create involuntary muscle contractions as a means to increase muscle strength, and
may be an effective treatment for improving muscle function and physical activity levels in
older adults with sarcopenia. Thus, it is critical to explore viable and effective
alternative therapies to increase physical activity. The goal of the investigators' is to
determine the effectiveness of neuromuscular electrical stimulation (NMES) at increasing
physical activity and related biological, psychological, and muscle function factors. This
placebo controlled clinical trial will use a pre-test - post-test randomized experimental
design.
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | March 2020 |
Est. primary completion date | March 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: - generally healthy men and women - ages 60 and older Exclusion Criteria: - 1) they have participated in regular resistance training exercise or physical rehabilitation of the lower extremity within 2 months of the study - 2) contraindicating conditions for electrical stimulation are present (i.e., swollen, infected or inflamed areas including open wounds, or painful areas on the lower limbs, implanted electronics including cardiac pacemakers, electronic infusion pumps, implanted stimulators, or surgical hardware in the lower limbs) - 3) they have current knee injury or knee pain - 4) have a neuromuscular disease - 5) currently taking insulin for diabetes regulation - 6) they have a history of seizures |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Texas State University |
Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004 Jan;52(1):80-5. — View Citation
Kemmler W, von Stengel S, Engelke K, Häberle L, Kalender WA. Exercise effects on bone mineral density, falls, coronary risk factors, and health care costs in older women: the randomized controlled senior fitness and prevention (SEFIP) study. Arch Intern Med. 2010 Jan 25;170(2):179-85. doi: 10.1001/archinternmed.2009.499. — View Citation
Kern H, Barberi L, Löfler S, Sbardella S, Burggraf S, Fruhmann H, Carraro U, Mosole S, Sarabon N, Vogelauer M, Mayr W, Krenn M, Cvecka J, Romanello V, Pietrangelo L, Protasi F, Sandri M, Zampieri S, Musaro A. Electrical stimulation counteracts muscle decline in seniors. Front Aging Neurosci. 2014 Jul 24;6:189. doi: 10.3389/fnagi.2014.00189. eCollection 2014. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Physical Activity | Physical activity will be measured from accelerometer data. | Physical activity levels will be assessed for 1 week before the intervention and for 1 week after the intervention period. The change in physical activity will be compared between these two time-periods. | |
Secondary | Change in Muscle Strength | Muscle strength will be measured by maximal voluntary contraction on a dynamometer. | Muscle strength will be assessed prior to the first day of the intervention, after 2-weeks of the intervention, and two days after the completion of the 4-week intervention. | |
Secondary | Change in Muscle Endurance | Muscle endurance time will be measured on a dynamometer. | Muscle endurance will be assessed prior to the first day of the intervention and 2 days after the completion of the 4-week intervention. | |
Secondary | Pre-training NMES-related change in glucose | Fasting blood glucose levels will be measured. | Blood glucose will be measured immediately before and immediately after the application of the intervention on the first (training Day 1) NMES intervention day. | |
Secondary | Post-training NMES-related change in glucose | Fasting blood glucose levels will be measured. | Blood glucose will be measured immediately before and immediately after the application of the intervention on the last day (training day 12) of the NMES intervention. | |
Secondary | Pre-training NMES-related change in Brain-derived Neurotrophic Factor (BDNF) levels | Brain-derived neurotrophic factor, a marker of neuronal growth, will be obtained from a blood sample. | BDNF levels will be measured immediately before and immediately after the application of the intervention on the first (training Day 1) NMES intervention day. | |
Secondary | Post-intervention change in Brain-derived Neurotrophic Factor (BDNF) levels | Brain-derived neurotrophic factor, a marker of neuronal growth, will be obtained from a blood sample. | BDNF levels will be measured immediately before and immediately after the application of the intervention on the last day (training day 12) of the NMES intervention. | |
Secondary | Change in self-efficacy of activities of daily living | Self-efficacy will be measured by survey. | Self-efficacy will be measured prior to the first day of the intervention and 4 days after the last day of the 4-week intervention. | |
Secondary | Change in motor activation | Motor activation will be measured by surface electromyography measures. | Motor activation will be measured prior to the first day of the intervention and two days after the completion of the 4-week intervention. | |
Secondary | Change in perception of pain | Perceived pain experienced during the NMES treatment will be measured by survey. | Perceptions of pain will be measured immediately after the NMES treatment on the first (training day 1) and last day (training day 12) of the 4-week intervention. | |
Secondary | Physical activity during the 4-week intervention | Physical activity will be measured from accelerometer data. | Physical activity levels will be measured during the 4 weeks of the intervention (from the first day of the intervention through the last day of the intervention). | |
Secondary | Change in timed up and go test | The timed up and go test will measure the time it takes to stand up from a chair, walk a few meters, turn around and sit back down. | Timed up and go test will be assessed prior to the first day of the intervention and 4 days after the last day of the 4-week intervention. | |
Secondary | Change in stair climb test | The stair climb test will assess the time it takes to safely ascend 10 stairs. | The stair cimb test test will be assessed prior to the first day of the intervention and 4 days after the last day of the 4-week intervention. | |
Secondary | Change in five repetition sit-to-stand test | The five repetition sit-to-stand test will assess the time it take to stand up and sit down on a chair 5 times. | The five repetition sit-to-stand test will be assessed prior to the first day of the intervention and 4 days after the last day of the 4-week intervention. | |
Secondary | Change in 6-min walk test | The 6-min walk test will assess the distance an individual can walk in 6 minutes. | The 6-min walk test will be assessed prior to the first day of the intervention and 4 days after the last day of the 4-week intervention. | |
Secondary | Change in grip strength | The grip strength test will measure the maximal hand grip strength of both hand using a grip strength dynamometer. | The grip strength test will be assessed prior to the first day of the intervention and 4 days after the last day of the 4-week intervention. | |
Secondary | Change in arm curl test | The arm curl test will measure the number of repetitions completed with a dumbbell. | The arm curl test will be assessed prior to the first day of the intervention and 4 days after the last day of the 4-week intervention. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06287502 -
Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis
|
N/A | |
Recruiting |
NCT05063279 -
RELIEF - Resistance Training for Life
|
N/A | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Recruiting |
NCT06143592 -
Inspiratory Muscle Training on Balance, Falls and Diaphragm Thickness in the Elderly
|
N/A | |
Terminated |
NCT04350762 -
Nutritional Supplementation in the Elderly With Weight Loss
|
N/A | |
Enrolling by invitation |
NCT05953116 -
Managing the Nutritional Needs of Older Filipino With Due Attention to Protein Nutrition and Functional Health Study
|
N/A | |
Recruiting |
NCT04028206 -
Resistance Exercise or Vibration With HMB for Sarcopenia
|
N/A | |
Enrolling by invitation |
NCT03297632 -
Improving Muscle Strength, Mass and Physical Function in Older Adults
|
N/A | |
Completed |
NCT04015479 -
Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults
|
N/A | |
Completed |
NCT03234920 -
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation
|
N/A | |
Recruiting |
NCT03998202 -
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
|
||
Recruiting |
NCT04717869 -
Identifying Modifiable PAtient Centered Therapeutics (IMPACT) Frailty
|
||
Completed |
NCT05497687 -
Strength-building Lifestyle-integrated Intervention
|
N/A | |
Completed |
NCT03119610 -
The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
|
Phase 1/Phase 2 | |
Recruiting |
NCT05711095 -
The Anabolic Properties of Fortified Plant-based Protein in Older People
|
N/A | |
Recruiting |
NCT05008770 -
Trial in Elderly With Musculoskeletal Problems Due to Underlying Sarcopenia - Faeces to Unravel Gut and Inflammation Translationally
|
||
Not yet recruiting |
NCT05860556 -
Sustainable Eating Pattern to Limit Malnutrition in Older Adults
|
||
Recruiting |
NCT04545268 -
Prehabilitation for Cardiac Surgery in Patients With Reduced Exercise Tolerance
|
N/A | |
Recruiting |
NCT04522609 -
Electrostimulation of Skeletal Muscles in Patients Listed for a Heart Transplant
|
N/A | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|